Analyst Ratings For Crispr Therapeutics (NASDAQ:CRSP)
Today, SunTrust Banks reiterated its Buy rating on Crispr Therapeutics (NASDAQ:CRSP) with a price target of $65.00.
Some recent analyst ratings include
- 3/9/2018-SunTrust Banks Reiterated Rating of Buy.
- 3/9/2018-Piper Jaffray Companies Reiterated Rating of Overweight.
- 3/8/2018-JMP Securities initiated coverage with a Mkt Outperform rating.
- 12/21/2017-Oppenheimer Reiterated Rating of Hold.
- 12/10/2017-Cann Reiterated Rating of Hold.
Recent Insider Trading Activity For Crispr Therapeutics (NASDAQ:CRSP)
Crispr Therapeutics (NASDAQ:CRSP) has insider ownership of 39.98% and institutional ownership of 27.29%.
- On 1/16/2018 Tyler Dylan-Hyde, Insider, sold 66,000 with an average share price of $28.03 per share and the total transaction amounting to $1,849,980.00.
- On 1/5/2018 Aktiengesellschaft Bayer, Major Shareholder, bought 527,472 with an average share price of $22.75 per share and the total transaction amounting to $11,999,988.00.
- On 1/5/2018 Kurt Von Emster, Director, sold 92,337 with an average share price of $26.96 per share and the total transaction amounting to $2,489,405.52.
- On 1/2/2018 Kurt Von Emster, Director, sold 37,754 with an average share price of $26.76 per share and the total transaction amounting to $1,010,297.04.
- On 1/2/2018 Tyler Dylan-Hyde, Insider, sold 38,000 with an average share price of $21.64 per share and the total transaction amounting to $822,320.00.
- On 12/29/2017 Tyler Dylan-Hyde, Insider, sold 31,000 with an average share price of $22.72 per share and the total transaction amounting to $704,320.00.
- On 12/28/2017 Tyler Dylan-Hyde, Insider, sold 700 with an average share price of $21.75 per share and the total transaction amounting to $15,225.00.
Recent Trading Activity for Crispr Therapeutics (NASDAQ:CRSP)
Shares of Crispr Therapeutics closed the previous trading session at 58.10 up +4.40 8.19% with 55.689998626708984 shares trading hands.
